Jennifer Jarrett Arcus Biosciences, Inc. (RCUS) insider trading activity

Jennifer Jarrett is Chief Operating Officer of Arcus Biosciences, Inc.. Currently has a direct ownership of 213,369 shares of RCUS, which is worth approximately $2.78 Million. The most recent transaction as insider was on Jan 23, 2025, when has been sold 50,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 213K

12.07% 3M change

28.61% 12M change

Total Value Held $2.78 Million

Jennifer Jarrett Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 23 2025	BUY Grant, award, or other acquisition	-	50,000 Added 18.98%	213,369 Common Stock
Dec 15 2024	SELL Payment of exercise price or tax liability	$442,216 $16.08 p/Share	27,501 Reduced 14.41%	163,369 Common Stock
Sep 15 2024	SELL Payment of exercise price or tax liability	$227,426 $17.95 p/Share	12,670 Reduced 6.24%	190,394 Common Stock
Jun 15 2024	SELL Payment of exercise price or tax liability	$215,009 $16.97 p/Share	12,670 Reduced 5.87%	203,064 Common Stock
Mar 27 2024	SELL Open market or private sale	$202,720 $17.55 p/Share	11,551 Reduced 5.09%	215,253 Common Stock
Mar 18 2024	SELL Open market or private sale	$245,175 $18.23 p/Share	13,449 Reduced 5.6%	226,804 Common Stock
Feb 27 2024	SELL Open market or private sale	$685,147 $20.11 p/Share	34,070 Reduced 12.42%	240,253 Common Stock
Feb 26 2024	SELL Open market or private sale	$492,818 $20.07 p/Share	24,555 Reduced 8.22%	274,323 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	40,000 Added 11.8%	298,878 Common Stock
Dec 22 2023	SELL Open market or private sale	$382,212 $17.76 p/Share	21,521 Reduced 7.68%	258,878 Common Stock
Dec 19 2023	SELL Sale (or disposition) back to the issuer	$207,890 $18.09 p/Share	11,492 Reduced 3.94%	280,399 Common Stock
Dec 18 2023	SELL Sale (or disposition) back to the issuer	$199,574 $17.74 p/Share	11,250 Reduced 3.71%	291,891 Common Stock
Sep 22 2023	SELL Open market or private sale	$427,166 $19.99 p/Share	21,369 Reduced 6.59%	302,691 Common Stock
Sep 18 2023	SELL Sale (or disposition) back to the issuer	$255,122 $20.4 p/Share	12,506 Reduced 3.72%	324,060 Common Stock
Jul 28 2023	SELL Open market or private sale	$911,250 $20.25 p/Share	45,000 Reduced 11.79%	336,566 Common Stock
Jun 22 2023	SELL Open market or private sale	$237,795 $19.12 p/Share	12,437 Reduced 3.16%	381,566 Common Stock
Jun 16 2023	SELL Open market or private sale	$243,094 $19.35 p/Share	12,563 Reduced 3.09%	394,003 Common Stock
Mar 16 2023	SELL Open market or private sale	$146,734 $16.81 p/Share	8,729 Reduced 2.1%	406,217 Common Stock
Jan 27 2023	SELL Open market or private sale	$37,632 $23.52 p/Share	1,600 Reduced 0.38%	414,946 Common Stock
Jan 26 2023	SELL Open market or private sale	$7,068 $23.56 p/Share	300 Reduced 0.07%	416,546 Common Stock
Jan 23 2023	BUY Grant, award, or other acquisition	-	45,800 Added 9.9%	416,846 Common Stock
Dec 16 2022	SELL Open market or private sale	$510,117 $30.95 p/Share	16,482 Reduced 10.04%	147,609 Common Stock
Sep 16 2022	SELL Open market or private sale	$333,152 $26.28 p/Share	12,677 Reduced 8.83%	130,942 Common Stock
Jun 17 2022	SELL Open market or private sale	$145,508 $22.0 p/Share	6,614 Reduced 5.28%	118,619 Common Stock
Jun 16 2022	SELL Open market or private sale	$125,998 $20.72 p/Share	6,081 Reduced 4.63%	125,233 Common Stock

Also insider at

SNDX

Syndax Pharmaceuticals Inc Healthcare

ARNA

ARENA PHARMACEUTICALS INC Healthcare

Director

SRZN

Surrozen, Inc. Healthcare

RDUS

Radius Health, Inc. Healthcare

Director

JATT-WT

JATT Acquisition Corp

SGMT

Sagimet Biosciences Inc.

Director